The palmoplantar pustulosis market size has grown strongly in recent years. It will grow from $2.09 billion in 2025 to $2.26 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to limited treatment options for chronic skin conditions, reliance on corticosteroids and topical agents, delayed diagnosis of pustular psoriasis, low patient awareness about disease management, hospital-centric care delivery.
The palmoplantar pustulosis market size is expected to see strong growth in the next few years. It will grow to $3.03 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to emergence of novel biologics and systemic therapies, increasing adoption of targeted immunomodulators, growth in teledermatology and digital health platforms, expansion of home-based phototherapy adoption, increasing online and retail pharmacy penetration. Major trends in the forecast period include rising adoption of biologic therapies, increasing use of targeted immunomodulators, expansion of home-based phototherapy solutions, integration of teledermatology for chronic skin disorders, growth in online pharmacy access for treatments.
The rising incidence of skin disorders is expected to drive growth in the palmoplantar pustulosis market in the coming years. Skin disorders are conditions that affect the structure, function, or appearance of the skin. The increasing prevalence of these disorders is influenced by environmental changes, lifestyle habits, and genetic predisposition. Environmental factors, such as air pollution, extreme weather, and exposure to harmful chemicals, can irritate the skin and contribute to conditions like eczema or acne. Palmoplantar pustulosis is a chronic skin disorder that primarily affects the palms and soles, causing pustules, redness, and scaling. Various treatments help manage symptoms, improve skin health, and alleviate discomfort. For example, in December 2023, the National Institutes of Health (NIH), a U.S.-based medical research organization, reported that the global prevalence of atopic dermatitis reached 2.6%, affecting approximately 204 million people worldwide. Therefore, the rising incidence of skin disorders is propelling growth in the palmoplantar pustulosis market.
Companies in the palmoplantar pustulosis market are focusing on novel therapies, such as monoclonal antibodies targeting inflammatory pathways, to improve patient outcomes. Monoclonal antibodies (mAbs) are identical antibodies produced by a single clone of B cells, designed to target specific antigens for therapeutic or diagnostic purposes. For instance, in August 2023, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, received partial approval for LUMICEF in Japan for treating palmoplantar pustulosis. LUMICEF is a targeted therapy that blocks IL-17, providing rapid and sustained relief for inflammatory skin conditions like psoriasis and palmoplantar pustulosis, reducing inflammation and improving patient quality of life.
In October 2024, Organon & Co., a US-based pharmaceutical company, acquired Dermavant Sciences Ltd. for an undisclosed amount. This acquisition allows Organon to strengthen its dermatology portfolio and enhance women’s health offerings by providing innovative treatments for chronic skin conditions. Dermavant Sciences Ltd., based in the US, develops therapies for immuno-dermatological conditions, focusing on unmet needs in areas such as plaque psoriasis and atopic dermatitis.
Major companies operating in the palmoplantar pustulosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., Bristol‑Myers Squibb Company, Novartis International AG, GlaxoSmithKline PLC (GSK), Amgen Inc., Chugai Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Kyowa Kirin Co. Ltd., Almirall S.A., MorphoSys AG, MoonLake Immunotherapeutics AG, Aristea Therapeutics Inc., AnaptysBio Inc., Kamari Pharma Ltd., Johnson & Johnson, AstraZeneca, Eli Lilly and Company, Bayer AG, Merck & Co. Inc., UCB S.A., Boehringer Ingelheim International GmbH, Arcutis Biotherapeutics, Affibody AB, LEO Pharma A/S, Galderma, Incyte Corporation, Takeda Pharmaceutical Company Ltd., Roivant Sciences.
North America was the largest region in the palmoplantar pustulosis market in 2025. The regions covered in the palmoplantar pustulosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the palmoplantar pustulosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the palmoplantar pustulosis market by increasing costs for imported biologic therapies, topical medications, and phototherapy equipment. Retail pharmacies, online platforms, and hospitals in regions such as north america, europe, and asia-pacific are most affected due to reliance on imported therapies. While tariffs have increased acquisition costs, they have also promoted domestic manufacturing, encouraged innovation in home-based and teledermatology solutions, and enhanced local access to advanced treatments.
The palmoplantar pustulosis market research report is one of a series of new reports that provides palmoplantar pustulosis market statistics, including palmoplantar pustulosis industry global market size, regional shares, competitors with a palmoplantar pustulosis market share, detailed palmoplantar pustulosis market segments, market trends and opportunities, and any further data you may need to thrive in the palmoplantar pustulosis industry. This palmoplantar pustulosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Palmoplantar pustulosis is a chronic skin disorder marked by the development of pustules - small, pus-filled blisters - on the palms and soles. It often causes redness, scaling, and thickened skin in these areas and can be painful. The condition is frequently associated with other skin disorders, such as psoriasis.
The main treatments for palmoplantar pustulosis include topical therapies, systemic therapies, biologics, and phototherapy. Topical treatments work to reduce inflammation, manage symptoms, and prevent flare-ups using corticosteroids, vitamin D analogs, calcineurin inhibitors, keratolytics, or coal tar. These treatments are applied in settings such as hospitals, dermatology clinics, and homecare, and are distributed through channels including online pharmacies, retail pharmacies, and hospitals.
The palmoplantar pustulosis market consists of revenues earned by entities by providing services such as personalized skincare and counseling, phototherapy services, pharmacological treatment services, and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The palmoplantar pustulosis market also includes sales of phototherapy devices, oral systemic therapies, medicated skincare products, topical corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The palmoplantar pustulosis market size is expected to see strong growth in the next few years. It will grow to $3.03 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to emergence of novel biologics and systemic therapies, increasing adoption of targeted immunomodulators, growth in teledermatology and digital health platforms, expansion of home-based phototherapy adoption, increasing online and retail pharmacy penetration. Major trends in the forecast period include rising adoption of biologic therapies, increasing use of targeted immunomodulators, expansion of home-based phototherapy solutions, integration of teledermatology for chronic skin disorders, growth in online pharmacy access for treatments.
The rising incidence of skin disorders is expected to drive growth in the palmoplantar pustulosis market in the coming years. Skin disorders are conditions that affect the structure, function, or appearance of the skin. The increasing prevalence of these disorders is influenced by environmental changes, lifestyle habits, and genetic predisposition. Environmental factors, such as air pollution, extreme weather, and exposure to harmful chemicals, can irritate the skin and contribute to conditions like eczema or acne. Palmoplantar pustulosis is a chronic skin disorder that primarily affects the palms and soles, causing pustules, redness, and scaling. Various treatments help manage symptoms, improve skin health, and alleviate discomfort. For example, in December 2023, the National Institutes of Health (NIH), a U.S.-based medical research organization, reported that the global prevalence of atopic dermatitis reached 2.6%, affecting approximately 204 million people worldwide. Therefore, the rising incidence of skin disorders is propelling growth in the palmoplantar pustulosis market.
Companies in the palmoplantar pustulosis market are focusing on novel therapies, such as monoclonal antibodies targeting inflammatory pathways, to improve patient outcomes. Monoclonal antibodies (mAbs) are identical antibodies produced by a single clone of B cells, designed to target specific antigens for therapeutic or diagnostic purposes. For instance, in August 2023, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, received partial approval for LUMICEF in Japan for treating palmoplantar pustulosis. LUMICEF is a targeted therapy that blocks IL-17, providing rapid and sustained relief for inflammatory skin conditions like psoriasis and palmoplantar pustulosis, reducing inflammation and improving patient quality of life.
In October 2024, Organon & Co., a US-based pharmaceutical company, acquired Dermavant Sciences Ltd. for an undisclosed amount. This acquisition allows Organon to strengthen its dermatology portfolio and enhance women’s health offerings by providing innovative treatments for chronic skin conditions. Dermavant Sciences Ltd., based in the US, develops therapies for immuno-dermatological conditions, focusing on unmet needs in areas such as plaque psoriasis and atopic dermatitis.
Major companies operating in the palmoplantar pustulosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., Bristol‑Myers Squibb Company, Novartis International AG, GlaxoSmithKline PLC (GSK), Amgen Inc., Chugai Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Kyowa Kirin Co. Ltd., Almirall S.A., MorphoSys AG, MoonLake Immunotherapeutics AG, Aristea Therapeutics Inc., AnaptysBio Inc., Kamari Pharma Ltd., Johnson & Johnson, AstraZeneca, Eli Lilly and Company, Bayer AG, Merck & Co. Inc., UCB S.A., Boehringer Ingelheim International GmbH, Arcutis Biotherapeutics, Affibody AB, LEO Pharma A/S, Galderma, Incyte Corporation, Takeda Pharmaceutical Company Ltd., Roivant Sciences.
North America was the largest region in the palmoplantar pustulosis market in 2025. The regions covered in the palmoplantar pustulosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the palmoplantar pustulosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the palmoplantar pustulosis market by increasing costs for imported biologic therapies, topical medications, and phototherapy equipment. Retail pharmacies, online platforms, and hospitals in regions such as north america, europe, and asia-pacific are most affected due to reliance on imported therapies. While tariffs have increased acquisition costs, they have also promoted domestic manufacturing, encouraged innovation in home-based and teledermatology solutions, and enhanced local access to advanced treatments.
The palmoplantar pustulosis market research report is one of a series of new reports that provides palmoplantar pustulosis market statistics, including palmoplantar pustulosis industry global market size, regional shares, competitors with a palmoplantar pustulosis market share, detailed palmoplantar pustulosis market segments, market trends and opportunities, and any further data you may need to thrive in the palmoplantar pustulosis industry. This palmoplantar pustulosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Palmoplantar pustulosis is a chronic skin disorder marked by the development of pustules - small, pus-filled blisters - on the palms and soles. It often causes redness, scaling, and thickened skin in these areas and can be painful. The condition is frequently associated with other skin disorders, such as psoriasis.
The main treatments for palmoplantar pustulosis include topical therapies, systemic therapies, biologics, and phototherapy. Topical treatments work to reduce inflammation, manage symptoms, and prevent flare-ups using corticosteroids, vitamin D analogs, calcineurin inhibitors, keratolytics, or coal tar. These treatments are applied in settings such as hospitals, dermatology clinics, and homecare, and are distributed through channels including online pharmacies, retail pharmacies, and hospitals.
The palmoplantar pustulosis market consists of revenues earned by entities by providing services such as personalized skincare and counseling, phototherapy services, pharmacological treatment services, and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The palmoplantar pustulosis market also includes sales of phototherapy devices, oral systemic therapies, medicated skincare products, topical corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Palmoplantar Pustulosis Market Characteristics
3. Palmoplantar Pustulosis Market Supply Chain Analysis
4. Global Palmoplantar Pustulosis Market Trends and Strategies
5. Palmoplantar Pustulosis Market Analysis of End Use Industries
7. Global Palmoplantar Pustulosis Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Palmoplantar Pustulosis Total Addressable Market (TAM) Analysis for the Market
9. Palmoplantar Pustulosis Market Segmentation
10. Palmoplantar Pustulosis Market Regional and Country Analysis
11. Asia-Pacific Palmoplantar Pustulosis Market
12. China Palmoplantar Pustulosis Market
13. India Palmoplantar Pustulosis Market
14. Japan Palmoplantar Pustulosis Market
15. Australia Palmoplantar Pustulosis Market
16. Indonesia Palmoplantar Pustulosis Market
17. South Korea Palmoplantar Pustulosis Market
18. Taiwan Palmoplantar Pustulosis Market
19. South East Asia Palmoplantar Pustulosis Market
20. Western Europe Palmoplantar Pustulosis Market
21. UK Palmoplantar Pustulosis Market
22. Germany Palmoplantar Pustulosis Market
23. France Palmoplantar Pustulosis Market
24. Italy Palmoplantar Pustulosis Market
25. Spain Palmoplantar Pustulosis Market
26. Eastern Europe Palmoplantar Pustulosis Market
27. Russia Palmoplantar Pustulosis Market
28. North America Palmoplantar Pustulosis Market
29. USA Palmoplantar Pustulosis Market
30. Canada Palmoplantar Pustulosis Market
31. South America Palmoplantar Pustulosis Market
32. Brazil Palmoplantar Pustulosis Market
33. Middle East Palmoplantar Pustulosis Market
34. Africa Palmoplantar Pustulosis Market
36. Palmoplantar Pustulosis Market Competitive Landscape and Company Profiles
37. Palmoplantar Pustulosis Market Other Major and Innovative Companies
40. Palmoplantar Pustulosis Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Palmoplantar Pustulosis Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses palmoplantar pustulosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for palmoplantar pustulosis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The palmoplantar pustulosis market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Treatment Type: Topical Treatments; Systemic Treatments; Biologics; Phototherapy2) By Distribution Channel: Online Pharmacies; Retail Pharmacies
3) By Application: Hospitals; Dermatology Clinics; Homecare Settings
Subsegments:
1) By Topical Treatments: Corticosteroids; Vitamin D Analogues; Calcineurin Inhibitors; Keratolytics2) By Systemic Treatments: Retinoids; Immunosuppressants; Phosphodiesterase-4 (PDE4) Inhibitors; Corticosteroids
3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-17 (IL-17) Inhibitors; Interleukin-23 (IL-23) Inhibitors; Interleukin-12/23 (IL-12/23) Inhibitors
4) By Phototherapy: Narrowband UVB Therapy (NB-UVB); Psoralen plus Ultraviolet A (PUVA) Therapy; Excimer Laser Therapy; Targeted Phototherapy
Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Sanofi S.A.; Bristol‑Myers Squibb Company; Novartis International AG; GlaxoSmithKline PLC (GSK); Amgen Inc.; Chugai Pharmaceutical Co. Ltd.; Janssen Pharmaceuticals Inc.; Kyowa Kirin Co. Ltd.; Almirall S.A.; MorphoSys AG; MoonLake Immunotherapeutics AG; Aristea Therapeutics Inc.; AnaptysBio Inc.; Kamari Pharma Ltd.; Johnson & Johnson; AstraZeneca; Eli Lilly and Company; Bayer AG; Merck & Co. Inc.; UCB S.A.; Boehringer Ingelheim International GmbH; Arcutis Biotherapeutics; Affibody AB; LEO Pharma A/S; Galderma; Incyte Corporation; Takeda Pharmaceutical Company Ltd.; Roivant Sciences
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Palmoplantar Pustulosis market report include:- Pfizer Inc.
- AbbVie Inc.
- Sanofi S.A.
- Bristol‑Myers Squibb Company
- Novartis International AG
- GlaxoSmithKline PLC (GSK)
- Amgen Inc.
- Chugai Pharmaceutical Co. Ltd.
- Janssen Pharmaceuticals Inc.
- Kyowa Kirin Co. Ltd.
- Almirall S.A.
- MorphoSys AG
- MoonLake Immunotherapeutics AG
- Aristea Therapeutics Inc.
- AnaptysBio Inc.
- Kamari Pharma Ltd.
- Johnson & Johnson
- AstraZeneca
- Eli Lilly and Company
- Bayer AG
- Merck & Co. Inc.
- UCB S.A.
- Boehringer Ingelheim International GmbH
- Arcutis Biotherapeutics
- Affibody AB
- LEO Pharma A/S
- Galderma
- Incyte Corporation
- Takeda Pharmaceutical Company Ltd.
- Roivant Sciences
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.26 Billion |
| Forecasted Market Value ( USD | $ 3.03 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
